Changes In BNP Research Articles

Improvement in Left Ventricular Diastolic Stiffness Induced by Physical Training in Patients With Dilated Cardiomyopathy

Background Diastolic dysfunction in long-term heart failure is accompanied by abnormal neurohormonal control and ventricular stiffness. The diastolic phase is determined by a balance between pressure gradients and intrinsic ventricular wall properties: according to a mathematical model, the latter (ie, left ventricular [LV] elastance, K LV) may be calculated by the formula: K LV = (70/[DT-20]) 2 mm Hg/mL, where DT is the transmitral Doppler deceleration time. Methods and Results In 54 patients with chronic systolic heart failure (39 men, 15 women; age 65 ± 10 years; New York Heart Association [NYHA], 2.3 ± 0.9; ejection fraction [EF], 32% ± 5%), we analyzed the relationship between K LV and an index of neurohormonal derangement (levels of brain natriuretic peptide [BNP]), and investigated whether 3 months of physical training could modulate diastolic operating stiffness. Patients were randomized to physical training (n = 27) or to a control group (n = 27). Before and after training, patients underwent Doppler echocardiogram and cardiopulmonary stress test. At baseline, ventricular stiffness was related to BNP levels ( P < .01). Training improved NYHA class, exercise performance, and estimated pulmonary pressure. BNP was reduced. Ventricular volumes, mean blood pressure, and EF remained unchanged. A 27% reduction of elastance was observed (K LV, 0.111 ± 0.044 from 0.195 ± 0.089 mm Hg/mL; P < .01), whose magnitude was related to changes in BNP ( P < .05) and to K LV at baseline ( P < .01). No changes in K LV were observed in controls after 3 months (0.192 ± 0.115 from 0.195 ± 0.121 mm Hg/mL). Conclusions In heart failure, left ventricular diastolic stiffness is related to neurohormonal derangement and is modified by physical training. This improvement in LV compliance could result from a combination of hemodynamic improvement and regression of the fibrotic process.

Alterations in Transmural Myocardial Strain

In asymptomatic patients with severe isolated mitral regurgitation (MR), identifying the onset of early left ventricular (LV) dysfunction can guide the timing of surgical intervention. We hypothesized that changes in LV transmural myocardial strain represent an early marker of LV dysfunction in an ovine chronic MR model. Sheep were randomized to control (CTRL, n=8) or experimental (EXP, n=12) groups. In EXP, a 3.5- or 4.8-mm hole was created in the posterior mitral leaflet to generate "pure" MR. Transmural beadsets were inserted into the lateral and anterior LV wall to radiographically measure 3-dimensional transmural strains during systole and diastolic filling, at 1 and 12 weeks postoperatively. MR grade was higher in EXP than CTRL at 1 and 12 weeks (3.0 [2-4] versus 0.5 [0-2]; 3.0 [1-4] versus 0.5 [0-1], respectively, both P<0.001). At 12 weeks, LV mass index was greater in EXP than CTRL (201+/-18 versus 173+/-17 g/m(2); P<0.01). LVEDVI increased in EXP from 1 to 12 weeks (P=0.015). Between the 1 and 12 week values, the change in BNP (-4.5+/-4.4 versus -3.0+/-3.6 pmol/L), PRSW (9+/-13 versus 23+/-18 mm Hg), tau (-3+/-11 versus -4+/-7 ms), and systolic strains was similar between EXP and CTRL. The changes in longitudinal diastolic filling strains between 1 and 12 weeks, however, were greater in EXP versus CTRL in the subendocardium (lateral: -0.08+/-0.05 versus 0.02+/-0.14; anterior: -0.10+/-0.05 versus -0.02+/-0.07, both P<0.01). Twelve weeks of ovine "pure" MR caused LV remodeling with early changes in LV function detected by alterations in transmural myocardial strain, but not by changes in BNP, PRSW, or tau.

Relationship between Survival and Basal and Early Changes in BNP, Nt-pBNP, and Big-ET-1 Found in EPHESUS Data

Relationship between Survival and Basal and Early Changes in BNP, Nt-pBNP, and Big-ET-1 Found in EPHESUS Data

Thirty Day Post Discharge BNP Levels Predict Outcomes Better Than Discharge Levels - Italian RED Study

Introduction: Heart failure (HF) patients often relapse into acute decompensation and consequent rehospitalization resulting in social and economic burdens. BNP has been previously shown to be prognostic at hospital discharge, but it has not been well characterized at time points after discharge from the emergency department (ED). Hypothesis: To determine the prognostic utility of BNP levels and changes in the emergency department (ED) and follow-up time-points. Methods: 276 HF patients were enrolled from 8 centers in Italy.

Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure

The long-term effect of beta-blockade on the plasma levels of natriuretic peptides BNP and its N-terminal counterpart, NT-proBNP, as risk markers in heart failure (HF) is obscure. Stable systolic HF patients from the CARMEN study were divided in groups matching their randomised treatment allocation: Carvedilol, enalapril or carvedilol+enalapril. Changes in BNP and NT-proBNP from baseline to 6 months maintenance visit were evaluated in each treatment arm. Furthermore, the prognostic value of BNP and NT-proBNP during monotherapy with carvedilol was assessed with univariate Cox proportional hazards models using a combined endpoint of all cause mortality and cardiovascular hospitalisation. NT-proBNP and BNP were significantly reduced after six months treatment with enalapril (NT-proBNP 1,303 to 857 pg/ml (P < 0.001), BNP 119 to 85 pg/ml (P < 0.001)) or carvedilol+enalapril (NT-proBNP 1,223 to 953 pg/ml (P = 0.003), BNP 117 to 93 pg/ml (P = 0.01)). In contrast, no change was observed in the carvedilol group (NT-proBNP 907 to 1,082 pg/ml (P = 0.06), BNP 114 to 130 pg/ml (P = 0.15). The prognostic value of NT-proBNP and BNP was maintained in the carvedilol group (NT-proBNP HR 1.018 95% CI (1.005-1.032), BNP 1.171 (1.088-1.260)). Treatment of HF patients with carvedilol alone does not reduce levels of natriuretic peptides, but treatment with enalapril does. Both BNP and NT-proBNP predict death and hospitalisation in HF patients treated with carvedilol for six months. The clinical implication of our results is that NT-proBNP and BNP can be used as risk markers of death and cardiovascular hospitalisations in systolic HF patients receiving carvedilol without ACE inhibition.

Atorvastatin-Induced Changes in Plasma Coenzyme Q10 and Brain Natriuretic Peptide in Patients With Coronary Artery Disease

The beneficial effects of statins in patients with coronary artery disease (CAD) may be balanced by concerns that statins can depress production of ubiquinone (CoQ10), which serves as a component of mitochondrial energy production and an antioxidant. Accordingly, the effects of atorvastatin (ATO)-induced changes in plasma CoQ10 on BNP and oxidative stress were investigated. In 29 patients with CAD, the plasma levels of CoQ10 and BNP and urinary excretion of 8-iso-prostaglandin F2alpha (8-iso-PGF) were determined before and after 3-month treatment with ATO. Ten patients had received pravastatin and 10 patients fluvastatin, while 9 patients had not received any statin before ATO. There was a linear correlation between ATO-induced changes in total cholesterol and CoQ10 (r = 0.632, P < 0.01), and an inverse correlation between ATO-induced changes in CoQ10 and BNP (r = -0.497, P < 0.01). There was no significant correlation between ATO-induced changes in CoQ10 and 8-iso-PGF. Multivariate analysis revealed that ATO-induced decreases in plasma CoQ10 were significantly associated with increasing BNP levels. In conclusion, long-term treatment with ATO might increase plasma levels of BNP in patients with CAD when it is accompanied by a greater reduction in plasma CoQ10. However, ATO-induced decreases in CoQ10 might not increase oxidative stress.

Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients

Recent advances in pharmacological and pacemaker-based treatments for heart failure (HF) have brought about significant improvements in left ventricular function. To identify the proportion of treated systolic HF patients in whom left ventricular systolic function improves and/or returns to normal. This was a retrospective analysis of 221 HF patients. Improvement in left ventricular function was defined as an improvement in ejection fraction (LVEF) of > or =10% on echocardiography. Return to normal was defined as an improvement of LVEF to > or =50% and a reduction in left ventricular end diastolic diameter to < or =55 mm. Changes in BNP were also recorded. Improvement in LVEF was observed in 44.3% of patients and return to normal systolic function in 10.9%, only 2.3% had both a return to normal echocardiographic parameters and a BNP<100 pg/ml. A higher percentage of the improved group were on target doses of beta-blockers (p=0.004). Baseline BNP was not a predictor of improvement. There was a trend towards a reduction in HF readmissions in the improved group (p=0.07) but no difference in the risk of death or all-cause readmission. While a substantial proportion of treated HF patients have an improvement in left ventricular function over time, only a small proportion return to normal dimensions and LVEF, underlining the permanent nature of ventricular damage in the vast majority of patients.

Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial

Plasma levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) are increased in patients with chronic heart failure (CHF). Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis. To assess the prognostic importance of NT-pro BNP at baseline and during follow-up, in patients in whom beta-blocker therapy is initiated. In COMET, 3029 patients with CHF in NYHA class II-IV and EF<35% were randomised to carvedilol or metoprolol tartrate and were followed for an average of 58 months. Blood samples were collected for the measurement of NT-pro BNP at baseline (n=1559) and during follow-up (n=309). Baseline plasma concentrations of NT-pro BNP above the median (1242 pg/ml) were associated with higher all-cause mortality (RR 2.77; 95% CI 2.33-3.3, p<0.001). Patients who achieved NT-pro BNP levels<400 pg/ml during follow-up had a lower subsequent mortality (RR 0.32; 95% CI 0.15-0.69, p=0.004). The plasma concentration of NT-pro BNP is a powerful predictor of mortality in patients with CHF. Patients who achieve an NT-pro BNP of <400 pg/ml subsequent to treatment with a beta-blocker have a favourable prognosis.

ANP and BNP in atrial fibrillation before and after cardioversion – and their relationship to cardiac volume and function

The role of atrial (ANP) and B-type (BNP) natriuretic peptide in atrial fibrillation (AF) is not clear. Our aim was to describe ANP and BNP in AF, and their changes following cardioversion in persistent AF. Furthermore, we wanted to assess the association between ANP and BNP and cardiac volume and function evaluated by magnetic resonance imaging. ANP and BNP decreased significantly following cardioversion. After 180 days of sinus rhythm, ANP and BNP were still significantly elevated. Same results were seen in patients with lone AF. Left and right atrial volumes correlated positively with ANP and BNP. Changes in left atrial volume were predictive of changes in ANP and BNP following cardioversion. AF may cause enduringly elevated ANP and BNP and atrial volume seems to be an important determinant of ANP and BNP in AF.

BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity

Background Cardiotoxity is a side-effect of cancer treatment with anthracycline that is currently monitored by measuring the left ventricular ejection fraction (LVEF) by gated equilibrium radionuclide ventriculography (RNV). We hypothesized that BNP measurements could replace, at least in part, the RNV examinations. Therefore, we studied whether BNP could be used, alone or in combination with RNV, in the monitoring of anthracycline-induced cardiotoxity. Methods A total of 333 patients undergoing anthracycline treatment had LVEF and BNP concentration measured. Of these, 73 had more than one determination. In the 333 patients we compared the BNP concentration to LVEF, and further, for the 73 patient with more than one examination, we compared the changes in LVEF and BNP. We evaluated different BNP cut-off values for detection of LVEF below 0.50, 0.45 and 0.40, respectively. Results Using LVEF below 0.50 and a BNP cut-off value of 100 pg ml − 1 it was possible to save 90% of the RNV determinations with the cost of overlooking 68% of the patients with reduced LVEF. Using LVEF below 0.45 and a BNP cut-off value of 30 pg ml − 1 it was possible to save 59% of the RNV determination, with the cost of overlooking 15% of the patients with reduced LVEF. Conclusion BNP cannot safely be used as an alternative to RNV determination of LVEF in patient undergoing anthracycline treatment if the standard limit of an LVEF of 0.50 was used. However, if only lower LVEF were to be detected BNP could be used to save RNV determinations.

500: Serial changes in BNP are not associated with changes in submaximal or maximal exercise or quality of life

potential HTx recipients and to identify characteristics that would risk-stratify patients for screening CT. Methods and Materials: This is a retrospective study of patients evaluated for HTx at Loyola from 2001-2005. Only pts with documented screening CTs were included in the statistical analysis (n 130). Risk factors for malignancy including smoking and alcohol history, age, and pre-transplant comorbidities were assessed. Additional tests resulting from an abnormal CT, such as further radiologic imaging, biopsies, and procedures, were documented. Results: Of 130 CTs performed, 75 (58%) were abnormal. The most common CT abnormality was a pulmonary nodule. To investigate abnormal findings, these additional tests were performed: 7 biopsies, 3 fine needle aspirations, 4 surgical excisions, 2 thoracenteses, 4 bronchoscopies, 2 EGDs, 17 ultrasounds, 40 follow-up CTs, 13 positron emission tomography (PET) scans, and 1 magnetic resonance imaging (MRI). Of these tests, 1 was positive for malignancy (renal cell carcinoma); this pt was not transplanted. Patients were followed for a mean of 989 days. One patient was diagnosed with a pulmonary squamous cell carcinoma 1 yr post-HTx and died; calcified granuloma and lymphadenopathy were seen on screening CT. Smoking and alcohol history, age, gender, race, and Epstein Barr virus were not statistically associated with a finding of malignancy. Conclusions: Pre-HTx screening CTs identified few abnormalities excluding pts from HTx, and resulted in many other costly studies. Only one malignancy was identified by screening CTs; we therefore did not identify any associated risk factors. Screening CTs may not be costeffective, and may not be necessary for routine HTx work-up.

A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural settings

Self-monitoring by heart failure (HF) patients of worsening symptoms caused by fluid overload is a cornerstone of HF care. Disease management has improved outcomes in HF; however, these resource-intensive programs are limited to urban centers and are generally unavailable in rural or limited health care access areas. This pilot study sought to determine whether a simplified education program focused on a single component of disease management (symptom recognition and management of fluid weight) could improve knowledge, patient-reported self-care behavior, and HF severity in a rural setting. This randomized clinical trial enrolled 36 rural HF patients into an intervention or control group. The intervention group received a simplified education program with a follow-up phone call focusing on symptom management delivered by a non-cardiac-trained nurse. Patient knowledge, self-care behaviors, and HF severity (B-natriuretic peptide [BNP]) were measured at enrollment and at 3 months. The sample was primarily white men and married with a mean age of 71 years and ejection fraction of 47%. There were no differences between groups in knowledge, self-care behaviors and BNP at baseline; however, knowledge and self-care behavior related to daily weights improved significantly at 3 months in the intervention group (P = .01 and .03, respectively). Although the changes in mean BNP at 3 months were in the hypothesized direction, the difference between the 2 groups was not significant. A simplified education program designed for use in resource scarce settings improves knowledge and patient-reported self-care behaviors. These findings are important in providing care to patients with HF in limited access settings but should be studied for longer periods in more heterogeneous populations.

Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?

Weight gain and increase in B-Type Natriuretic Peptide have been advocated as means of aiding diagnosis of heart failure. However, there are few data to support the use of these criteria in diagnosing clinical deterioration in patients with established disease. This prospective study examines the sensitivity and specificity of absolute and relative changes in BNP and weight in determining the early onset of clinical deterioration in patients with established heart failure. All patients who presented to the outpatient clinic with completed self-reported daily weight books, baseline BNP measurement, outpatient BNP measurement and assessment by a cardiologist blinded to BNP and weight were included. Each patient was determined as clinically stable (CS) or in clinical deterioration (CD). Receiver operating characteristic (ROC) curves and sensitivity and specificity calculations for various absolute and relative BNP and weight changes were carried out. Weight and BNP changes were examined in 34 CS presentations (mean age 69.5+/-16.1 years) and 43 CD presentations (mean age 70.0+/-10.6 years). ROC analysis demonstrated that neither weight nor BNP changes in absolute or relative values predicted clinical deterioration in this study population adequately (AUC values ranging from 0.64 to 0.66). These data demonstrate that increase in body weight and BNP in isolation are not sensitive in assessing clinical deterioration in established heart failure. These observations may need to be emphasized in patient education and to physicians involved in assessment of heart failure patients.

257 CHF with restrictive pattern of transmitral flow: do BNP changes have a prognostic impact?

257 CHF with restrictive pattern of transmitral flow: do BNP changes have a prognostic impact?

Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction

The heart is a major site of natriuretic peptides (NP). Atrial and brain natriuretic peptide (ANP and BNP) are predominantly produced by atria and ventricles. C-Natriuretic peptide (CNP) is also found in heart tissue. ANP and BNP are produced by cardiomyocytes and fibroblasts. Cardiac fibroblasts also secrete CNP. Three NP-receptors (NPR-A, NPRB, NPR-C) are expressed in heart atria and ventricles. Baseline plasma BNP is a sensitive predictor of morbidity and mortality in heart failure and changes in BNP over time are associated with corresponding changes in subsequent mortality and morbidity. Plasma BNP, and to a lesser extent ANP, is also a strong cardiovascular risk marker in patients with essential hypertension and left ventricular hypertrophy without left ventricle dysfunction or overt renal disease. However, evidence to date suggests that plasma BNP levels should not be viewed as a diagnostic test for chronic heart failure and sequential assays of BNP have not been shown to be useful in the follow-up or the initiation of appropriate therapy. However, patients who present with dyspnea with unclear but suspected cardiac etiologies may be considered to have venous blood taken for the measurement of BNP level to assist with diagnostic decision and therefore appropriate management of the dyspnea. BNP level is however not a stand-alone test and must be used in conjunction with careful clinical evaluation and in patients with an intermediate pre-test likelihood of heart failure.

237 Poor sensitivity of weight and BNP changes in predicting clinical deterioration of HF

237 Poor sensitivity of weight and BNP changes in predicting clinical deterioration of HF

Relationship between Changes in Ejection Fraction, BNP and Norepinephrine over Time and the Effect of Valsartan in Val-HeFT

Relationship between Changes in Ejection Fraction, BNP and Norepinephrine over Time and the Effect of Valsartan in Val-HeFT

Plasma concentrations of atrial and brain natriuretic peptides and cyclic guanosine monophosphate in response to dobutamine infusion in patients with surgically repaired tetralogy of fallot.

We examined the plasma concentrations of atrial and brain natriuretic peptides (ANP and BNP) and cyclic guanosine monophosphate (cGMP) during dobutamine infusion and their relationship with hemodynamic parameters in 14 patients with surgically repaired tetralogy of Fallot (TOF). Dobutamine was infused at an initial dose of 5 microgram/kg/min and increased by 5 microgram/kg/min up to 20 microgram/kg/min. The plasma ANP, BNP, and cGMP concentrations were determined before infusion, at the end of each stage, and 15 minutes after discontinuing dobutamine infusion. The plasma concentrations of ANP, BNP, and cGMP were elevated in all patients before dobutamine infusion. The ANP, BNP, and cGMP concentrations decreased in 11 of the 14 patients during dobutamine infusion. In contrast, the plasma ANP and BNP concentrations increased in the remaining 3 patients without a change in the cGMP concentration. The right ventricular pressure and volume were significantly elevated in these patients. The plasma cGMP concentration correlated with the ANP concentration (r = 0.62, p < 0.01) but not the BNP concentration. The plasma ANP concentration during dobutamine infusion correlated with right ventricular systolic pressure (r = 0.71, p < 0.05), mean right atrial pressure (r = 0.29, p < 0.05), and mean pulmonary capillary wedge pressure (r = 0.32, p < 0.05). The BNP concentration correlated with right ventricular volume (r = 0.61, p < 0.05) and systolic pressure (r = 0. 46, p < 0.05). In conclusion, rapid changes in ANP, BNP, and cGMP concentrations during dobutamine infusion reflect the changes in atrial and ventricle pressure and volume overload. In surgically repaired TOF, the ANP concentration is affected by right ventricular systolic pressure, right atrial pressure, and pulmonary capillary pressure. Furthermore, the BNP concentration reflects right ventricular pressure and volume overload.